[go: up one dir, main page]

WO2002034920A3 - Regulation de la proteine de type ceruloplasmine humaine - Google Patents

Regulation de la proteine de type ceruloplasmine humaine Download PDF

Info

Publication number
WO2002034920A3
WO2002034920A3 PCT/EP2001/012158 EP0112158W WO0234920A3 WO 2002034920 A3 WO2002034920 A3 WO 2002034920A3 EP 0112158 W EP0112158 W EP 0112158W WO 0234920 A3 WO0234920 A3 WO 0234920A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
regulation
ceruloplasmin
human ceruloplasmin
reagents
Prior art date
Application number
PCT/EP2001/012158
Other languages
English (en)
Other versions
WO2002034920A2 (fr
Inventor
Zhimin Zhu
Original Assignee
Bayer Ag
Zhimin Zhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Zhimin Zhu filed Critical Bayer Ag
Priority to AU2002219046A priority Critical patent/AU2002219046A1/en
Publication of WO2002034920A2 publication Critical patent/WO2002034920A2/fr
Publication of WO2002034920A3 publication Critical patent/WO2002034920A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0091—Oxidoreductases (1.) oxidizing metal ions (1.16)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90283—Oxidoreductases (1.) acting on superoxide radicals as acceptor (1.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des réactifs qui régulent l'activité de la protéine de type céruloplasmine humaine et des réactifs qui se lient aux produits géniques de la protéine de type céruloplasmine humaine, lesquels réactifs peuvent être utilisés pour réguler l'activité de la céruloplasmine. La régulation de l'activité de la céruloplasmine est utilisée en particulier pour traiter les troubles cardiovasculaires, les troubles hépatiques comme dans la maladie de Wilson, et les troubles du système nerveux central comme dans la maladie de Parkinson.
PCT/EP2001/012158 2000-10-24 2001-10-22 Regulation de la proteine de type ceruloplasmine humaine WO2002034920A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002219046A AU2002219046A1 (en) 2000-10-24 2001-10-22 Regulation of human ceruloplasmin-like protein

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24242600P 2000-10-24 2000-10-24
US60/242,426 2000-10-24
US31379601P 2001-08-22 2001-08-22
US60/313,796 2001-08-22

Publications (2)

Publication Number Publication Date
WO2002034920A2 WO2002034920A2 (fr) 2002-05-02
WO2002034920A3 true WO2002034920A3 (fr) 2002-11-28

Family

ID=26935082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/012158 WO2002034920A2 (fr) 2000-10-24 2001-10-22 Regulation de la proteine de type ceruloplasmine humaine

Country Status (2)

Country Link
AU (1) AU2002219046A1 (fr)
WO (1) WO2002034920A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013091008A1 (fr) * 2011-12-20 2013-06-27 The Mental Health Research Institute Of Victoria Procédé de traitement d'une fonctionnalité réduite de la céruloplasmine dans le système nerveux central
KR20240159714A (ko) * 2023-04-27 2024-11-06 국립해양생물자원관 다중구리 산화효소 활성 도메인의 개량 펩타이드를 포함하는 구리대사 관련 신경계 질환의 예방 또는 치료용 조성물
CN118715208A (zh) * 2023-10-20 2024-09-27 广东工业大学 治疗威尔逊氏病的特异性四齿铜螯合剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025954A2 (fr) * 1996-12-09 1998-06-18 Samuel David Gpi-ceruloplasmine, ses analogues et procedes d'utilisation
WO1998039448A2 (fr) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 nouvelles proteines secretees
WO2001040466A2 (fr) * 1999-12-01 2001-06-07 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
WO2001051636A2 (fr) * 2000-01-14 2001-07-19 Incyte Genomics, Inc. Proteines secretees

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025954A2 (fr) * 1996-12-09 1998-06-18 Samuel David Gpi-ceruloplasmine, ses analogues et procedes d'utilisation
WO1998039448A2 (fr) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 nouvelles proteines secretees
WO2001040466A2 (fr) * 1999-12-01 2001-06-07 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
WO2001051636A2 (fr) * 2000-01-14 2001-07-19 Incyte Genomics, Inc. Proteines secretees

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 23 November 1999 (1999-11-23), XP002210153, retrieved from EBI Database accession no. AL030998 *
ISHIKAWA K-I ET AL: "PREDICTION OF THE CODING SEQUENCES OF UNIDENTIFIED HUMAN GENES. X. THE COMPLETE SEQUENCES OF 100 NEW CDNA CLONES FROM BRAIN WHICH CAN CODE FOR LARGE PROTEINS IN VITRO", DNA RESEARCH, UNIVERSAL ACADEMY PRESS, JP, vol. 5, no. 3, 30 June 1998 (1998-06-30), pages 169 - 176, XP000980105, ISSN: 1340-2838 *
VULPE CD ET AL.: "Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse", NATURE GENETICS, vol. 21, 1999, pages 195 - 199, XP002210151 *

Also Published As

Publication number Publication date
AU2002219046A1 (en) 2002-05-06
WO2002034920A2 (fr) 2002-05-02

Similar Documents

Publication Publication Date Title
WO2002004610A3 (fr) Regulation d'une enzyme humaine du type dipeptidyl-peptidase iv
WO2002034920A3 (fr) Regulation de la proteine de type ceruloplasmine humaine
WO2002020731A3 (fr) Regulation de l'enzyme humaine du type proteine disulfide isomerase
WO2001068839A3 (fr) Regulation de la proteine de type du recepteur de la lipoxine a4 humaine
WO2001077149A3 (fr) Regulation d'une proteine gpcr type cyslt2 humaine
WO2002022631A3 (fr) Regulation d'une enzyme de type pyroglutamyl peptidase humaine
WO2002062975A3 (fr) Regulation de la proteine humaine du type elongase hselo1
WO2002057461A3 (fr) Regulation de la metalloprotease a zinc de type adam-ts humaine
WO2002081705A3 (fr) Regulation de la proteine humaine de type acetyltransferase gnat
WO2003033708A3 (fr) Regulation de la proteine kinase humaine a serine/threonine
WO2001068840A3 (fr) REGULATION DE LA PROTEINE HUMAINE SEMBLABLE A ACYLE CoA/INHIBITEUR DE LIAISON DU DIAZEPAM
WO2002055694A3 (fr) Polynucleotides et polypeptides de genes metaboliques et leurs utilisations
WO2002046403A3 (fr) Regulation de la proteine humaine du type 'patched'
WO2003035862A3 (fr) Regulation d'une proteine contenant une signature d'arginase humaine
WO2003025174A3 (fr) Regulation de la proteine humaine de type mrp1
WO2002026999A3 (fr) Regulation de la proteine humaine de type adam-ts
WO2003023034A3 (fr) Regulation de tau-tubuline kinase humaine
WO2002018566A3 (fr) Regulation d'enzyme de type l-asparaginase humaine
WO2002012460A3 (fr) Régulation de la protéine s'apparentant à la monoamine oxydase humaine
WO2003033709A3 (fr) Regulation de la proteine kinase serine/threonine humaine
WO2002044351A3 (fr) Regulation de la coa ligase humaine d'acides gras
WO2002055556A3 (fr) Regulation de la proteine a canal de potassium a porte de tension humaine kv2.2
WO2002032938A3 (fr) Regulation de la proteine humaine de type pgc-1
WO2002081706A3 (fr) Regulation d'une proteine de type phosphatase humaine
WO2002081666A3 (fr) Regulation de la proteine humaine de type phosphatase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP